智通财经APP获悉，东阳光长江药业(01558)尾盘涨近5%，截至发稿，涨4.52%，报13.86港元，成交额2.47亿港元。
消息面上，国产创新药企业不断释放自身的创新价值，三生制药近期刷新国产创新药BD纪录。据悉，2024年11月25日，东阳光药发布公告，授予三生制药附属公司沈阳三生苯磺酸克立福替尼在中国关于特定适应症的独家商业化权益。此次BD合作也是东阳光药继与Apollo Therapeutics达成9亿美元BD交易后，在2024年11月份以来的第二个License-out合作交易。
摩根士丹利近日发布研报称，上调东阳光长江药业目标价11.1%，从12.6港元升至14港元，维持“增持”评级。大摩指，将2027-2030年盈利预测上调2-11%，对该公司的基本假设认为，预计2025年及以后年销售额将稳定在约40亿元人民币或以上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.